GlassScriptPhysician profile
Jeffery C Weeks
NPI 1538100011
$15,141.17
in general payments reported to CMS, 2019-2025
43 companies · $2,766 in 2025
The $2,766 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $998 · 2021: $1,808 · 2022: $2,234 · 2023: $2,339 · 2024: $3,223 · 2025: $2,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,228 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,228.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,027.97 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,952.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,151.76 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,030.11 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $779.10 | 2019-2025 | |
| Pfizer INC. | $769.92 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $763.82 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Leo Pharma INC. | $662.03 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $638.36 | 2022-2025 | Sotyktu |
| Amgen INC. | $567.17 | 2019-2025 | Otezla, Otezla, Enbrel |
| Galderma Laboratories, L.P. | $501.97 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $488.98 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $464.56 | 2019-2025 | Siliq, Targretin, Duobrii |
| Mayne Pharma Commercial LLC | $389.20 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $356.59 | 2023-2025 | Zoryve |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $248.99 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $179.13 | 2019-2025 | Bimzelx |
| Revance Therapeutics, INC. | $126.96 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.04 | 2023-2025 | Spevigo |
| Celgene Corporation | $111.58 | 2019 | |
| Genentech USA, INC. | $100.78 | 2019-2022 | |
| Almirall LLC | $93.23 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $88.55 | 2020-2021 | |
| Journey Medical Corporation | $80.36 | 2025 | |
| Organon LLC | $50.50 | 2024-2025 | |
| Dusa Pharmaceuticals, INC. | $41.30 | 2019 | |
| Kerecis Limited | $38.67 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $37.84 | 2023 | Puraply |
| Aclaris Therapeutics, INC. | $31.52 | 2019 | |
| Convatec INC. | $29.65 | 2025 | |
| Dermira, INC. | $26.39 | 2019 | |
| Dermavant Sciences, INC. | $20.61 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $18.98 | 2024 | Ycanth |
| Botanix Sb INC | $18.30 | 2025 | Sofdra |
| Taro Pharmaceuticals USA, INC. | $17.87 | 2019 | |
| Fresenius Kabi USA, LLC | $15.91 | 2023 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $15.77 | 2021 | |
| Allergan, INC. | $15.64 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.28 | 2022 | |
| Merz North America, INC. | $13.70 | 2025 | |
| Merck Sharp & Dohme LLC | $12.90 | 2019 | |
| Allegis Pharmaceuticals, LLC | $12.04 | 2023 | Spinosad |
| Biofrontera INC. | $11.70 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.